Trial Profile
A Phase 1 Study of Lenalidomide in Combination With Vorinostat in Pediatric Patients With High Grade or Progressive Central Nervous System Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Vorinostat (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 08 Mar 2021 Status changed from suspended to discontinued.
- 15 May 2019 Status changed from recruiting to suspended.
- 15 Feb 2017 New trial record